Earnings results for Sage Therapeutics (NASDAQ:SAGE)
Sage Therapeutics, Inc. is expected* to report earnings on 02/24/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 10 analysts’ forecasts, the consensus EPS forecast for the quarter is $-2.17. The reported EPS for the same quarter last year was $-3.25.
Analyst Opinion on Sage Therapeutics (NASDAQ:SAGE)
18 Wall Street analysts have issued ratings and price targets for Sage Therapeutics in the last 12 months. Their average twelve-month price target is $80.05, predicting that the stock has a possible downside of 2.77%. The high price target for SAGE is $135.00 and the low price target for SAGE is $28.00. There are currently 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Sage Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 9 buy ratings, 9 hold ratings, and no sell ratings. According to analysts’ consensus price target of $80.05, Sage Therapeutics has a forecasted downside of 2.8% from its current price of $82.33. Sage Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Sage Therapeutics (NASDAQ:SAGE)
Sage Therapeutics does not currently pay a dividend. Sage Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Sage Therapeutics (NASDAQ:SAGE)
In the past three months, Sage Therapeutics insiders have not sold or bought any company stock. Only 4.80% of the stock of Sage Therapeutics is held by insiders.
Earnings and Valuation of Sage Therapeutics (NASDAQ:SAGE
Earnings for Sage Therapeutics are expected to grow in the coming year, from ($8.83) to ($3.14) per share. The P/E ratio of Sage Therapeutics is -7.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Sage Therapeutics is -7.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Sage Therapeutics has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here